NCT06123377 Angiogenic Factors in the Conservative Management of Gestational Hypertension
| NCT ID | NCT06123377 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Saint Thomas Hospital, Panama |
| Condition | Gestational Hypertension |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2026-08-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2024-06-01 with a primary completion date of 2026-08-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hypertensive disorders of pregnancy (HPT) are an important cause of maternal-feto-neonatal morbidity and mortality, being one of the three leading causes of maternal death in our country and in developing countries. The only cure for THE is termination of pregnancy, which ends up being a decision in which gestational age and maternal risks must be balanced. Angiogenic factors have come to occupy an indispensable place in the arsenal of tools that can be used to separate the patient with a high likelihood of complications from those in whom prolongation of pregnancy could represent an important neonatal benefit. One of the most controversial scenarios is gestational hypertension, a group of hypertensive disorders considered the mildest form of the pre-eclamptic spectrum, where current recommendations indicate termination of pregnancy at 37 weeks. However, the decision is based on outdated guidelines developed at a time when angiogenic factors were just beginning to be known. The purpose of the study is to use angiogenic factors as a guide to decide the most appropriate gestational age for termination of pregnancy in patients diagnosed with gestational hypertension.
Eligibility Criteria
Inclusion Criteria: * Pregnant women between 24 and 40 weeks of gestation. * Diagnosis of Gestational Hypertension based on ACOG criteria * index sFlt-1/PIGF equal or below 33 Exclusion Criteria: * Multiple gestation * Maternal vasculitis * Previous cesarean section (3 or more) * Neurological conditions * Chronic renal disease * Purpura * Heart disease * Index sFlt-1/PIGF of 34 or more
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06123377 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Gestational Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06123377 currently recruiting?
Yes, NCT06123377 is actively recruiting participants. Contact the research team at oreyespanama@yahoo.es for enrollment information.
Where is the NCT06123377 trial being conducted?
This trial is being conducted at Panama City, Panama.
Who is sponsoring the NCT06123377 clinical trial?
NCT06123377 is sponsored by Saint Thomas Hospital, Panama. The trial plans to enroll 150 participants.